Apolipoprotein A-I (ApoA-I), immunity, inflammation and cancer

150Citations
Citations of this article
137Readers
Mendeley users who have this article in their library.

Abstract

Apolipoprotein A-I (ApoA-I), the major protein component of high-density lipoproteins (HDL) is a multifunctional protein, involved in cholesterol traffic and inflammatory and immune response regulation. Many studies revealing alterations of ApoA-I during the development and progression of various types of cancer suggest that serum ApoA-I levels may represent a useful biomarker contributing to better estimation of cancer risk, early cancer diagnosis, follow up, and prognosis stratification of cancer patients. In addition, recent in vitro and animal studies disclose a more direct, tumor suppressive role of ApoA-I in cancer pathogenesis, which involves anti-inflammatory and immune-modulatory mechanisms. Herein, we review recent epidemiologic, clinicopathologic, and mechanistic studies investigating the role of ApoA-I in cancer biology, which suggest that enhancing the tumor suppressive activity of ApoA-I may contribute to better cancer prevention and treatment.

Cite

CITATION STYLE

APA

Georgila, K., Vyrla, D., & Drakos, E. (2019, August 1). Apolipoprotein A-I (ApoA-I), immunity, inflammation and cancer. Cancers. MDPI AG. https://doi.org/10.3390/cancers11081097

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free